Pharm-Olam International Opens a New Office in Paris, France; Continues Global Expansion

HOUSTON, TEXAS – Pharm-Olam International Ltd., a multi-national, full-service Clinical Research Solutions Organization (CRO) to biopharmaceutical and device industries, is proud to announce the opening of a new, fully-staffed office in Paris, France.

The Paris office, to be managed by Frederique Fauduet, Director of Clinical Development, will consist of members from Pharm-Olam’s Project Management, Clinical Operations, Regulatory, and Medical Writing teams. “In France we have always had a strong scientific and academic history and even today there are currently over 4000 open clinical studies around the country. You can find key opinion leaders in all the major fields working at the leading French medical institutes. Several improvements in the regulatory process coupled with the EU Horizon 2020 initiative and the R&D Tax Credit scheme have helped France continue to be one of the leaders of clinical research within the EU,” explained Ms. Fauduet.

John Hovre, Chief Operating Officer at Pharm-Olam, explains the latest addition to the Pharm-Olam family: “Pharm-Olam has had an operational presence in France for over 10 years but it is the only major market in Europe where we did not have a dedicated office. We have now rectified this and are proud to provide our customers office-based staff throughout Europe. We now have 20 operating offices across Western, Central and Eastern Europe. Europe is an important market for Pharm-Olam and compliments our presence in the Americas, Africa and Asia very well. We are looking to build our presence across the globe and we will be announcing further expansion plans in the near future.” For more information about Pharm-Olam, please contact info@pharm-olam.com (link sends e-mail).

About Pharm-Olam International Group

Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit contact us.